Mitral regurgitation is a disease in which the mitral valve is no longer performing optimally, causing blood leakage into the left atrium. A prevailing issue with current MR patients, is that many are not eligible for surgery and therefore do not have any treatment options available. 4C Medical Technologies is developing a minimally invasive technology that addresses mitral regurgitation, and that could be an option for these patients. The company’s AltaValve has won multiple awards for its innovative design. The easy-to-use solution involves the insertion of a flexible implant into the left atrium through a catheter. The supra-annular positioning and atrial-only fixation minimize the risks of blood flow obstruction to the aorta, and limit interaction with the left ventricle. This decreases the risks of complications for the patient.
As a startup, 4C Medical Technologies is facing a long road in putting their device on the market. In our webinar, Dr. Kumar outlines that a great idea alone isn’t enough. Understanding the anatomy of patients and the dynamic nature of structures, knowing the sizes of the device to select for the target population. All these issues and more, need to be confidently explained to investors and regulatory bodies. Materialise supported 4C Medical in bringing their concept to patient care. Take advantage of this webinar to learn about the development process and how to approach future plans.